Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 9
Submit an article Journal homepage
3,757
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma

Oliver Van OekelenIcahn School of Medicine at Mount Sinai, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-5824-197XView further author information
ORCID Icon,
Samir ParekhIcahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence[email protected]
View further author information
,
Hearn J. ChoIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Nivetha VishnuvardhanAlbert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USAView further author information
,
Deepu MadduriIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Joshua RichterIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Chun IpIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Kenneth LauIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Erika FlorendoIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Ines S. ManciaIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Joanne ThomasIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Daniel VerinaIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Elaine ChanIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Katarzyna ZarychtaIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Lisa LaIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Gina StrumoloIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
David T. MelnekoffIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Violetta V. LeshchenkoIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Seunghee Kim-SchulzeIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Suzana CoutoCelgene Corporation, Translational Development and Diagnostics, Summit, NJ, USAView further author information
,
Maria WangCelgene Corporation, Translational Development and Diagnostics, Summit, NJ, USAView further author information
,
William E. PierceallCelgene Corporation, Translational Development and Diagnostics, Summit, NJ, USAView further author information
,
Anjan ThakurtaCelgene Corporation, Translational Development and Diagnostics, Summit, NJ, USAView further author information
,
Alessandro LaganàIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
,
Sundar JagannathIcahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
&
Ajai ChariIcahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0405-7480View further author information
ORCID Icon show all
Pages 2208-2215 | Received 01 May 2020, Accepted 28 Jul 2020, Published online: 19 Aug 2020

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, Patricia Walker, Anthony Schwarer, Andrew W. Roberts, Philip Campbell, Robin Filshie, Sam Norton, John Reynolds, Mary Young, William Pierceall, Anjan Thakurta, Manman Guo, Udo Oppermann, Maria Wang, Yan Ren, Nola Kennedy, Samir Parekh & Andrew Spencer. (2021) Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Leukemia & Lymphoma 62:12, pages 2981-2991.
Read now

Articles from other publishers (6)

Faith E. Davies, Xavier Leleu, Prisca Vogel, Sujith Dhanasiri, Pauline Le Nouveau & Katja Weisel. (2023) A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure. Clinical Lymphoma Myeloma and Leukemia 23:11, pages 829-837.e1.
Crossref
Annamaria Brioli, Laura Gengenbach, Katia Mancuso, Mascha Binder, Thomas Ernst, Florian H. Heidel, Thomas Stauch, Elena Zamagni, Inken Hilgendorf, Andreas Hochhaus, Monika Engelhardt & Marie von Lilienfeld-Toal. (2023) Pomalidomide combinations are a safe and effective option after daratumumab failure. Journal of Cancer Research and Clinical Oncology 149:9, pages 6569-6574.
Crossref
Haotian Shi, Wei Wei, Rong Peng, Haimin Chen, Nian Zhou, Lixia Wu, Wenjun Yu, Wenhao Zhao, Jian Hou & Fan Zhou. (2023) Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications. Frontiers in Oncology 13.
Crossref
Joseph Franz, Elizabeth Myrus, Larysa Sanchez & Joshua Richter. (2023) No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma. Blood Reviews 57, pages 100993.
Crossref
Efstathios Kastritis, Evangelos Terpos & Meletios A. Dimopoulos. (2022) How I treat relapsed multiple myeloma. Blood 139:19, pages 2904-2917.
Crossref
Fredrik Schjesvold & Albert Oriol. (2021) Current and Novel Alkylators in Multiple Myeloma. Cancers 13:10, pages 2465.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.